3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
57
Recurrence
7
Neoplasms, Plasma Cell
6
Lymphoma
6
Immunoglobulin Light-chain Amyloidosis
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thalassemia
1
Sarcoma, Myeloid
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Interventions
peginterferon alfa-2b
1
liposomal doxorubicin
1
dolutegravir
1
belinostat
1
Zidovudine
1
Tenofovir
1
Taxes
1
Paclitaxel
1
Lomustine
1
Irinotecan
1
Introns
1
Gemcitabine
1
Doxorubicin
1
Cyclophosphamide
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia-Lymphoma, Adult T-Cell
×
Bortezomib
×
90 days
×
Clear all
No trials found.